PMID- 37809045
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231031
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Print)
IS  - 1792-1074 (Linking)
VI  - 26
IP  - 5
DP  - 2023 Nov
TI  - Identification of immunogenic cell death‑related prognostic signatures in 
      pancreatic cancer.
PG  - 473
LID - 10.3892/ol.2023.14061 [doi]
LID - 473
AB  - Targeting immunogenic cell death (ICD) may enable the response of pancreatic 
      cancer to immune checkpoint inhibitors (ICIs). The aim of the present study was 
      to elucidate the role of ICD-related genes in pancreatic cancer. Utilizing the 
      k-means method, consensus clustering was employed to effectively group patients 
      with pancreatic cancer. Subsequently, a set of differentially expressed genes was 
      identified between the two subtypes related to ICD, facilitating the execution of 
      a comprehensive enrichment analysis. Furthermore, the construction of an 
      ICD-related prognostic signature (IRPS) was accomplished through LASSO Cox 
      regression, thereby enabling the assessment of responses to both chemotherapy and 
      immunotherapy. In addition, the biological functionality of 5'-nucleotidase ecto 
      (NT5E) was elucidated through experimental investigations. Patients characterized 
      as the ICD high subtype experienced a comparatively shorter overall survival. 
      This subtype exhibited a noteworthy correlation with HLA families and immune 
      checkpoint molecules, underscoring its immunological significance. Subsequently, 
      patients with elevated IRPS risk scores displayed resistance towards 
      immunotherapy interventions. Of note, synergistic downregulation of NT5E in 
      combination with Gemcitabine was observed to significantly induce tumor cell 
      apoptosis, emphasizing its potential therapeutic value. Leveraging ICD-related 
      genes, a novel classification system was meticulously devised to comprehensively 
      evaluate both the clinical outcomes and therapeutic responses of patients 
      diagnosed with pancreatic cancer.
CI  - Copyright: (c) Yu et al.
FAU - Yu, Wenjing
AU  - Yu W
AD  - Department of Laboratory Medicine, The 13th People's Hospital of Chongqing, 
      Chongqing 400053, P.R. China.
FAU - Li, Mei
AU  - Li M
AD  - Department of Laboratory Medicine, The 13th People's Hospital of Chongqing, 
      Chongqing 400053, P.R. China.
FAU - Xia, Jing
AU  - Xia J
AD  - Department of Laboratory Medicine, The 13th People's Hospital of Chongqing, 
      Chongqing 400053, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20230920
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC10551861
OTO - NOTNLM
OT  - TCGA
OT  - immune checkpoint inhibitor
OT  - immunogenic cell death
OT  - pancreatic cancer
OT  - tumor immune microenvironment
COIS- The authors declare that they have no competing interests.
EDAT- 2023/10/09 06:42
MHDA- 2023/10/09 06:43
PMCR- 2023/09/20
CRDT- 2023/10/09 05:50
PHST- 2022/12/12 00:00 [received]
PHST- 2023/08/22 00:00 [accepted]
PHST- 2023/10/09 06:43 [medline]
PHST- 2023/10/09 06:42 [pubmed]
PHST- 2023/10/09 05:50 [entrez]
PHST- 2023/09/20 00:00 [pmc-release]
AID - OL-26-5-14061 [pii]
AID - 10.3892/ol.2023.14061 [doi]
PST - epublish
SO  - Oncol Lett. 2023 Sep 20;26(5):473. doi: 10.3892/ol.2023.14061. eCollection 2023 
      Nov.